Background Multimorbidity and the associated use of multiple medicines (polypharmacy), is
common in the older population. Despite this, there is no consensus definition for …

As the worldwide population ages, oncologists are often required to make difficult and
complex decisions regarding the treatment of older people (aged 65 years and older) with …

The NCCN Guidelines for Older Adult Oncology address specific issues related to the
management of cancer in older adults, including screening and comprehensive geriatric …

Purpose Polypharmacy is prevalent in older adults starting cancer treatment and associated
with potentially inappropriate medications (PIM), potential drug-drug interactions (DDI), and …

Polypharmacy is a highly prevalent problem in older persons, and is challenging to assess
and improve due to variations in definitions of the problem and the heterogeneous methods …

More and more elderly people with cancer are treated in oncology clinics worldwide every
year, many of whom have comorbid disorders treated with one or more drugs. Moreover …

Many forms of cancer present with a complex metabolic profile characterised by loss of lean
body mass known as cancer cachexia. The physical impact of cachexia contributes to …

OBJECTIVES: To identify patient characteristics associated with polypharmacy and
inappropriate medication (PIM) use among older patients with newly diagnosed cancer …

Cancer is the leading cause of death in older adults aged 60 to 79 years. The biology of
certain cancers and responsiveness to therapy changes with the patient's age. Advanced …

PURPOSE Providing a geriatric assessment (GA) summary with management
recommendations to oncologists reduces clinician-rated toxicity in older patients with …